Breast Cancer: Understanding Diagnosis and Treatment Options

Breast cancer is a complex disease characterized by the abnormal and uncontrolled growth of cells within breast tissue, forming a localized tumor or mass. If left untreated, malignant cells can invade surrounding tissues or metastasize through the lymphatic system or bloodstream to distant organs.

1. What Is Breast Cancer?

Breast cancer typically originates in one of two main anatomical structures of the breast:

• Ductal Carcinoma: Begins in the epithelial lining of the milk ducts that carry milk to the nipple. This represents the most common form of breast cancer.
• Lobular Carcinoma: Originates in the lobules, the glandular structures responsible for producing milk.

Molecular Subtypes:

Pathological analysis classifies breast tumors based on specific hormone and protein receptor status, which guides target-specific treatment decisions:

• Hormone Receptor-Positive (HR+): Tumor growth is stimulated by estrogen (ER+) or progesterone (PR+).
• HER2-Positive: Characterized by the overexpression of the human epidermal growth factor receptor 2 (HER2) protein.
• Triple-Negative Breast Cancer (TNBC): Lacks estrogen, progesterone, and HER2 receptors; typically requires systemic systemic therapy due to its aggressive nature.

2. How Breast Cancer Is Diagnosed

A. Screening and Early Detection

• Screening Mammogram: Low-dose X-ray imaging of the breast utilized to detect non-palpable lesions before symptoms arise, recommended annually for women from age 40.
• Clinical & Self Breast Examination: Physical palpation checking for painless lumps, skin dimpling, nipple inversion, or focal discharge.

B. Diagnostic Evaluation

1. Diagnostic Mammogram: Specialized, targeted imaging providing magnification and detailed views of suspicious microcalcifications or masses.
2. Breast Ultrasound: Differentiates between solid masses and fluid-filled simple or complex cysts.
3. Breast MRI: High-resolution magnetic resonance imaging recommended for high-risk patients or for defining exact tumor extent prior to surgery.
4. Biopsy (Definitive Diagnosis): Histopathological evaluation of tissue core samples removed via core needle or image-guided biopsy.
   • Clinical Purpose: Confirms malignancy, identifies tumor grade, and quantifies essential ER, PR, and HER2 receptor expression.

C. Clinical Staging

Following histological confirmation, secondary imaging (such as CT scans, PET-CT, or bone scans) determines whether metastasis has occurred. Staging progresses from Stage 0 (carcinoma in situ) to Stage IV (advanced metastatic disease).

3. Treatment Methods

Treatment plans are tailored based on molecular subtype, tumor size, disease stage, overall health, and individual preference.

A. Surgical Interventions

• Lumpectomy (Breast-Conserving Surgery): Surgical removal of the primary tumor alongside a clear margin of surrounding healthy tissue.
• Mastectomy: Complete surgical removal of the affected breast tissue.
• Axillary Lymph Node Evaluation: Sentinel lymph node biopsy or axillary dissection to evaluate regional lymphatic spread.

B. Radiation Therapy

Utilizes targeted high-energy radiation beams to eradicate residual microscopic cancer cells in the chest wall or regional lymph nodes, routinely indicated following lumpectomy or high-risk mastectomy.

C. Systemic Chemotherapy

Employs cytotoxic medications to eliminate rapidly dividing cancer cells throughout the body.

• Neoadjuvant Chemotherapy: Administered prior to surgery to shrink large tumors and facilitate breast-conserving procedures.
• Adjuvant Chemotherapy: Administered following surgery to destroy micro-metastases and lower recurrence risk.

D. Hormone (Endocrine) Therapy

Indicated for hormone receptor-positive tumors to block hormone binding or suppress systemic estrogen production:

• Tamoxifen: Selective estrogen receptor modulator (SERM) typically prescribed for premenopausal women.
• Aromatase Inhibitors (Letrozole, Anastrozole, Exemestane): Enzyme inhibitors indicated primarily for postmenopausal women.

E. Targeted Biological Therapy

Utilizes precision pharmacotherapy designed to interfere with specific molecular pathways driving tumor growth:

• HER2-Targeted Agents: Monoclonal antibodies such as Trastuzumab (Herceptin) and Pertuzumab for HER2-overexpressing tumors.
• PARP Inhibitors: Targeted oral agents for patients with germline BRCA1 or BRCA2 genetic mutations.

F. Immunotherapy

Monoclonal antibodies (such as pembrolizumab) that boost the host immune response to recognize and destroy malignant cells, primarily utilized in advanced or high-risk triple-negative breast cancer.

G. Integrative & Supportive Care

Comprehensive supportive care encompassing pain management, lymphedema physiotherapy, psychological support, and nutritional counseling throughout treatment.

4. Early Detection and Screening Guidelines

Regular diagnostic screening remains the most effective intervention for reducing breast cancer mortality:

• Women Aged 40–54: Annual screening mammograms are strongly recommended.
• Women Aged 55 and Older: Biennial or annual mammography based on individual risk profiles.
• High-Risk Individuals (Family history or BRCA1/2 mutation carriers): Supplemental screening, including annual Breast MRI alongside mammography, should begin earlier under medical supervision.